Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

BACKGROUND: Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses. We ai...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet Oncol
Päätekijät: Teply, Benjamin A, Wang, Hao, Luber, Brandon, Sullivan, Rana, Rifkind, Irina, Bruns, Ashley, Spitz, Avery, DeCarli, Morgan, Sinibaldi, Victoria, Pratz, Caroline F, Lu, Changxue, Silberstein, John L, Luo, Jun, Schweizer, Michael T, Drake, Charles G, Carducci, Michael A, Paller, Channing J, Antonarakis, Emmanuel S, Eisenberger, Mario A, Denmeade, Samuel R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5875180/
https://ncbi.nlm.nih.gov/pubmed/29248236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30906-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia